Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

BMC Psychiatry

Research Article

Shigenobu Kanba¹  David P McDonnell²  Juan-Carlos Gomez²  Michael Case²  Hideaki Katagiri³  Shinji Fujikoshi³  Michihiro Takahashi⁴  Mauricio Tohen⁵ 

[1] Kyushu University, Fukuoka, Japan;East Asian Bipolar Forum, Fukuoka, Japan;Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA;Lilly Research Laboratories, Sannomiya Plaza Bldg., 7-1-5, 651-0086, Isogamidori, Chuo-ku, Kobe, Japan;Lilly Research Laboratories, Sannomiya Plaza Bldg., 7-1-5, 651-0086, Isogamidori, Chuo-ku, Kobe, Japan;Takahashi Psychiatric Clinic, Ashiya, Hyogo, Japan;University of New Mexico Department of Psychiatry, Albuquerque, New Mexico, USA;

关键词: Bipolar disorder;    Bipolar depression;    Olanzapine;    Efficacy;    Safety;    Monotherapy;    Japan;    Japanese;   

DOI  :  10.1186/1471-244X-13-138

 received in 2012-09-19, accepted in 2013-04-01,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundThe efficacy and safety of olanzapine monotherapy are evaluated in Japanese patients from a large, global study of bipolar depression.MethodsThis is an analysis of Japanese patients from a 6-week, global (Japan, China, Korea, Taiwan, and the United States), randomized, double-blind, placebo-controlled, Phase 3 study of patients with a depressive episode of bipolar I disorder. The primary outcome was baseline-to-endpoint change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Secondary outcome measures included the Clinical Global Impressions-Bipolar Version Severity of Illness Scale (CGI-BP), the 17-item Hamilton Depression Rating Scale (HAMD-17) total score, the Young Mania Rating Scale (YMRS) total score, and rates of response (≥50% baseline-to-endpoint reduction in MADRS total score), recovery, and remission.ResultsOf the 156 Japanese patients, 104 had been allocated to olanzapine and 52 to placebo. All results are baseline-to-endpoint change. Compared to placebo, patients in the olanzapine group experienced greater improvement in the primary outcome measure, MADRS total score (−14.9 vs. −10.7; p = .01). They also had greater reductions in the following secondary measures: CGI- BP Depression (−1.41 vs. -0.89; p = .008), CGI-BP Bipolar (−1.31 vs. −0.83; p = .01), HAMD-17 (−11.7 vs. −7.9; p < .01), and YMRS (-0.32 vs. 0.34; p = .03). Differences in rates of response, recovery, and remission were not statistically significant. A greater proportion of olanzapine-treated patients reported treatment- emergent adverse events (87.5% vs. 59.6%; p < .001). Patients treated with olanzapine had greater increases in weight (p < .001) and fasting total cholesterol (p = .008); fasting triglycerides (p = .02), and fasting low-density lipoprotein (p = .01). There was a greater reduction in fasting high-density lipoprotein in olanzapine-treated patients (p = .01). Compared with placebo-group patients, more olanzapine-group patients shifted from borderline to high cholesterol (25.0% vs. 0.0%; p = .007) and had clinically significant weight gain (≥7% body weight) (20.2% vs. 1.9%; p = .001).ConclusionsResults of this analysis support the efficacy and tolerability of olanzapine for the treatment of bipolar depression in Japanese patients. Results in this population were consistent with those seen in the more ethnically diverse parent study. In making treatment decisions for individual patients, clinicians should carefully consider the risks and benefits of olanzapine treatment.Trial RegistrationClinicatrials.gov ID NCT00510146 Olanzapine Treatment of Patients with Bipolar I Disorder

【 授权许可】

CC BY   
© Katagiri et al.; licensee BioMed Central Ltd. 2013